Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00290823
Other study ID # 05IN214
Secondary ID 05-I-N214
Status Completed
Phase Phase 3
First received February 9, 2006
Last updated February 2, 2017
Start date April 2006
Est. completion date March 2011

Study information

Verified date February 2017
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether a short course of increased corticosteroid dosing with tapered dosing decreases seizure frequency as compared to standard corticosteroid dosing in patients with neurocysticercosis (NCC).


Description:

NCC is the most common parasitic infection of the central nervous system (CNS). It is caused by ingestion of eggs from a tapeworm of genus Taenia. Inflammation, seizures, or neurologic problems may occur in a patient with NCC. Corticosteroids are the current standard of care for NCC patients, but corticosteroids have many side effects. Albendazole is used to treat infections caused by worms; however, it is unclear if its use with the corticosteroid dexamethasone will decrease seizure frequency in NCC patients. The purpose of this study is to evaluate the efficacy of reducing seizure frequency with a short course of dexamethasone with tapered dosing when given with albendazole, as compared to standard dexamethasone and albendazole treatment, in NCC patients.

In this open label study, patients will be randomly assigned to one of two arms. Group I will receive 6 mg dexamethasone daily for 10 days only. Group II will receive 6 mg dexamethasone daily for 10 days, then 8 mg dexamethasone daily for 4 weeks with a 2-week taper. Both groups will also receive albendazole and omeprazole (a medicine that helps prevent gastroesophageal disease [GERD], a side effect of corticosteroid use). There will be 13 study visits over a 360-day period. Blood collection will occur at most visits. Group II will also undergo sputum smears and rapid culture testing on Days 14, 28, and 42. Patients will undergo magnetic resonance imaging (MRI) at screening and on Day 180 and computed tomography (CT) scanning on Day 360.


Other known NCT identifiers
  • NCT00344396

Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date March 2011
Est. primary completion date March 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Diagnosed with intraparenchymal NCC with 20 or fewer active cysts, as confirmed by enzyme-linked immunoelectrotransfer blot (EITB)

- Diagnosed with epilepsy secondary to NCC, with history of one or more spontaneous seizures within the 6 months prior to study entry

- Willingness to be hospitalized for a minimum of 2 weeks for this study

- PPD negative OR negative smears for tuberculosis (TB) if PPD positive

- Willing to use acceptable forms of contraception during the study and for at least 1 month after albendazole therapy

Exclusion Criteria:

- Primary generalized seizures not caused by NCC

- Subarachnoid or ventricular NCC

- Any vesicular lesion greater than 2 cm in diameter

- Previous therapy with albendazole or praziquantel within 2 years of study entry. Patients who have previously received single-dose albendazole for intestinal parasites are not excluded.

- Intracranial hypertension, as confirmed by CT or MRI

- History of status epilepticus

- Focal neurological defects

- Unstable or consistently abnormal vital signs (e.g., body temperature, pulse, respiratory rate, blood pressure)

- Cysts in critical regions, including brainstem or the eyes

- Pulmonary TB

- History of TB in the patient or history of TB in close contact of patient

- Chest x-ray suggestive of past or current TB

- Diabetes

- Systemic conditions (e.g., chronic kidney failure, liver disease, heart failure, steroid-dependent immune diseases) other than NCC that may interfere with the study

- Predicted survival time of less than 1 year

- Inability to undergo CT or MRI

- Hypersensitivity to albendazole, antiepileptic drugs, or contrast

- Hypertension at rest

- Require corticosteroids, received corticosteroids in the 4 weeks prior to study entry, or received corticosteroids for 9 or more days within the 6 months prior to study entry

- Other CNS processes that may interfere with study assessments

- Pregnancy or breastfeeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Albendazole
400 mg tablet taken orally twice daily
Dexamethasone
6mg or 8mg taken daily
Omeprazole
20 mg tablet taken orally daily

Locations

Country Name City State
Peru Instituto Especializado en Ciencias Neurologicas Lima

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

Peru, 

References & Publications (3)

Del Brutto OH. Neurocysticercosis. Semin Neurol. 2005 Sep;25(3):243-51. Review. — View Citation

Garcia HH, Gilman R, Martinez M, Tsang VC, Pilcher JB, Herrera G, Diaz F, Alvarado M, Miranda E. Cysticercosis as a major cause of epilepsy in Peru. The Cysticercosis Working Group in Peru (CWG). Lancet. 1993 Jan 23;341(8839):197-200. — View Citation

Medina MT, Rosas E, Rubio-Donnadieu F, Sotelo J. Neurocysticercosis as the main cause of late-onset epilepsy in Mexico. Arch Intern Med. 1990 Feb;150(2):325-7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative frequency of partial, generalized, and total seizures Through Day 42
Secondary Cumulative frequency of generalized seizures Throughout study
See also
  Status Clinical Trial Phase
Completed NCT00527579 - PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB Phase 1
Completed NCT00526916 - PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28 Phase 1
Terminated NCT02233855 - People Presenting With Neurocysticercosis in North America
Recruiting NCT00001205 - Natural History of Treated Neurocysticercosis and Long-Term Outcomes
Completed NCT02234570 - Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole Phase 1
Terminated NCT02947581 - Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO) Phase 3
Completed NCT02243644 - Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT Phase 3
Not yet recruiting NCT06376396 - Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis Phase 4
Completed NCT03874689 - Investigation of Environmental Factors Associated With Transmission of T. Solium in Endemic Villages of Zambia
Completed NCT00441285 - Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ) Phase 2/Phase 3
Not yet recruiting NCT04706819 - Parenchymal and Extraparenchymal Neurocysticercosis-A Registry Based Study
Completed NCT00283699 - A Pilot Study of Neurocysticercosis Treatment Phase 3
Terminated NCT02945527 - Treatment of Peri-calcification Edema in Neurocysticercosis (NCC) Phase 2/Phase 3
Completed NCT03834337 - Treatment of Patients With Active Neurocysticercosis in Eastern Africa
Completed NCT03851419 - The Burden of (Neuro)Cysticercosis Among People Living With HIV in Rural Tanzania